Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

From Idea to Data: An Agentic Architecture for the Clinical Trial Life Cycle.

Studies in health technology and informatics·2026
Same author

LLM-Assisted Clinical Data Harmonization: Combining Automated ETL Generation with Semantic Vocabulary Mapping for OMOP CDM.

Studies in health technology and informatics·2026
Same author

Interpretable Feature Extraction from Clinical Notes for Sepsis Prediction: Comparing Rule-Based, LLM, and Hybrid Approaches.

Studies in health technology and informatics·2026
Same author

OMOP Extraction of Medical Text Using LLMs: Preliminary Results.

Studies in health technology and informatics·2026
Same author

Bridging Theory and Practice: A Matrix-Based Approach to Teaching Medical Data Science with MIMIC-IV Demo Dataset.

Studies in health technology and informatics·2026

Video Experimental Relacionado

Updated: Jul 18, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Terapia génica: el gen terapéutico que causa el linfoma.

Niels-Bjarne Woods1, Virginie Bottero, Manfred Schmidt

  • 1Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.

Nature
|April 28, 2006
PubMed
Resumen

La terapia génica para la inmunodeficiencia grave combinada vinculada a X (X-SCID) utilizando el gen IL2RG puede plantear riesgos. Los estudios muestran que el propio gen terapéutico puede contribuir al desarrollo del linfoma de células T en modelos de ratón.

Más Videos Relacionados

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Videos de Experimentos Relacionados

Last Updated: Jul 18, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Área de la Ciencia:

  • Inmunología Inmunología.
  • Terapia génica Terapia génica La terapia génica es una terapia genética.
  • Oncología Oncología.

Sus antecedentes:

  • La terapia génica que utiliza células madre hematopoyéticas ha demostrado ser prometedora para el tratamiento de la inmunodeficiencia grave combinada vinculada a X (X-SCID).
  • Sin embargo, ensayos recientes han visto el desarrollo de leucemia de células T en pacientes tratados, lo que provocó una reevaluación de la seguridad de este enfoque.

Objetivo del estudio:

  • Investigar el potencial papel oncogénico del gen IL2RG, el gen terapéutico correctivo utilizado en la terapia génica X-SCID.
  • Evaluar el riesgo de desarrollo de linfoma de células T asociado con la terapia génica IL2RG en un modelo preclínico.

Principales métodos:

  • Se utilizó un modelo de ratón para simular la terapia génica para X-SCID.
  • El estudio se centró en el impacto del gen IL2RG como agente terapéutico.

Principales resultados:

  • Se encontró que el gen IL2RG contribuye al desarrollo de linfomas de células T en una porción significativa (un tercio) de los animales tratados.
  • Este hallazgo desafía la suposición anterior de que IL2RG es mínimamente oncogénico.

Conclusiones:

  • La terapia génica para X-SCID que utiliza el gen IL2RG puede conllevar un riesgo inherente de inducir linfomas de células T.
  • Estos hallazgos requieren una cuidadosa reevaluación de los protocolos de seguridad y el análisis de riesgo-beneficio para los ensayos de terapia génica X-SCID.